References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2020-3-117-124

mrj-1053

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Комментарии к обновленным рекомендациям Американской коллегии ревматологов по лечению подагры. Уратснижающие препараты (часть 1)

Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1)

Елисеев

М. С.

Eliseev

M. S.

Максим Сергеевич Елисеев

115522, Москва, Каширское шоссе, 34А

Maksim Sergeevich Eliseev

34A, Kashirskoe Shosse, Moscow 115522

elicmax@rambler.ru

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2020

21092020

143117124

2020

Елисеев М.С.

Eliseev M.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1053

Появление обновленных рекомендаций Американской коллегии ревматологов (American College of Rheumatology, ACR) по лечению подагры может послужить предпосылкой для ревизии проекта отечественных федеральных клинических рекомендаций (ФКР). Несмотря на некоторые отличия, следует отметить сходство обоих рекомендаций по ключевым пунктам, касающимся принципов медикаментозной коррекции гиперурикемии, показаний к назначению и алгоритмов применения конкретных лекарственных средств. Близость позиций прослеживается и в вопросе о необходимости приоритетного использования ингибиторов ксантиноксидазы (аллопуринол и фебуксостат) для уратснижающей терапии (УСТ), которая направлена на реализацию целевого принципа лечения подагры – строгого, постоянного контроля сывороточного уровня мочевой кислоты (его значение не должно превышать 6 мг/дл, или 360 мкмоль/л). Практические результаты проведения УСТ в соответствии с основными принципами, изложенными в ФКР, были опубликованы ранее.

The emergence of updated American College of Rheumatology (ACR) guidelines for the management of gout may serve as a prerequisite for revising the draft Russian Federal Clinical Guidelines (FCGs). Despite some differences, it should be noted that both guidelines are similar in key points concerning the principles of drug correction of hyperuricemia, indications for prescription and algorithms for the use of specific medicaments. The proximity of positions can be also traced in the need for the priority use of xanthine oxidase inhibitors (allopurinol and febuxostat) for urate-lowering therapy (ULT), which is aimed at implementing the target principle of gout management – the strict, constant control of serum levels of uric acid (its value should not exceed 6 mg/dl, or 360 μmol/l). The practical results of ULT in accordance with the basic principles outlined in the FCG have been published earlier.

подаграмочевая кислотауратснижающая терапияфебуксостаталлопуринол

gouturic acidurate-lowering therapyfebuxostatallopurinol

Статья спонсируется «ФП «Оболенскoе» (OBL Pharm).

This article has been supported by Obolenskoe (OBL Pharm).

References1

FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6): 744-60. doi:10.1002/acr.24180.

Подагра. Клинические рекомендации. http://cr.rosminzdrav.ru/#!/recomend/174.

Gout. Clinical recommendations. http://cr.rosminzdrav.ru/#!/recomend/174.

Gaffo AL, Dalbeth N, Saag KG, et al. Brief Report: Validation of a Definition of Flare in Patients With Established Gout. Arthritis Rheumatol. 2018; 70(3):462-7. doi:10.1002/art.40381.

Baraf HS, Becker MA, Gutierrez-Urena SR, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013;15(5):R137. doi:10.1186/ar4318.

Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188-94. doi:10.1093/rheumatology/ken457.

Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken). 2012;64(10):1431-46. doi: 10.1002/acr.21772

Елисеев МС. Хроническая болезнь почек: роль гиперурикемии и возможности уратснижающей терапии. Современная ревматология. 2018;12(1):60-5. doi:10.14412/1996-70122018-1-60-65.

Eliseev MS. Chronic kidney disease: the role of hyperuricemia and the possibility of uratelowering therapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(1): 60-5. (In Russ.). doi:10.14412/1996-70122018-1-60-65.

Perez Ruiz F, Richette P, Stack AG et al. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5(2): e001015. doi:10.1136/rmdopen-2019-001015

Kim SH, Lee SY, Kim JM, Son CN. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis. Korean J Intern Med. 2020 Jul;35(4):998-1003. doi: 10.3904/kjim.2018.423. Epub 2019 Apr 8.

Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and CrystalAssociated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592-1600. doi:10.1136/annrheumdis-2019-215933.

Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048-52. doi:10.1136/annrheumdis-2017-212288

Kimura K, Hosoya T, Uchida S, et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis. 2018; 72(6):798-810. doi:10.1053/j.ajkd.2018.06.028.

Liu P, Wang H, Zhang F, et al. The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. Intern Med. 2015; 54(17):2129-37. doi:10.2169/internalmedicine.54.4310

Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707.

Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522-8. doi: 10.1136/annrheumdis-2016-210872.

Stamp LK, Chapman PT, Barclay M, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open – label extension study. Ann Rheum Dis. 2017;76(12): 2065-70. doi: 10.1136/annrheumdis-2017211873.

Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J. 2008;49(5):384-7.

Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of Renal Function During Gout Treatment With Febuxostat: A Quantitative Study. Postgrad Med. 2013 Jan;125(1):106-14. doi: 10.3810/pgm.2013.01.2626.

Foody J, Turpin RS, Tidwell BA, et al. Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor. Am Health Drug Benefits. 2017 Nov;10(8): 393-401.

Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012 Aug;64(8):2529-36. doi: 10.1002/art.34488.

Новикова АМ, Елисеев МС. Терапия подагры при сниженной функции почек. Эффективная фармакотерапия. 2020;16(13):24-9.

Novikova AM, Eliseev MS. Treatment of gout with reduced kidney function. Effektivnaya farmakoterapiya. 2020;16(13): 24-9. (In Russ.).

Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014 Nov 14; (11):CD010457. doi: 10.1002/14651858.CD010457.pub2.

Чикина МН. Профилактика приступов артрита при назначении уратснижающей терапии у больных подагрой. Научно-практическая ревматология. 2018;56(6):760-6. doi:10.14412/1995-4484-2018-760-766.

Chikina MN. Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(6):760-6. (In Russ.). doi:10.14412/1995-4484-2018-760-766.

Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2): 270-6. doi:10.1136/annrheumdis-2017211574.

Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545-9. doi:10.1136/ard.57.9.545

Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;68(6):892-7. doi:10.1136/ard.2008.091462.

Wright DF, Duffull SB, Merriman TR, et al. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016; 81(2):277-89. doi:10.1111/bcp.12799.

Елисеев МС, Новикова АМ. По следам исследования CARES: сердечно-сосудистая безопасность фебуксостата. Русский медицинский журнал. 2020; (7):39–42.

Eliseev MS, Novikova AM. In the wake of the CARES study: cardiovascular safety of febuxostat. Russkii meditsinskii zhurnal. 2020; (7):39–42. (In Russ.).

Yu J, Qiu Q, Liang L, et al. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2018;28(2):339-44. doi:10.1080/14397595.2017.1318467.

Eliseev M, Chikina M, Nasonov E. Prophylaxis of Acute Arthritis at Initiation of Urate-Lowering Therapy in Gout Patients. In: Recent Advances in Gout. 2019. P. 57-70.

Chikina M, Eliseev M. Comparison of efficacy and safety of different anti-inflammatory drugs at initiation of urate-lowering therapy in patients with gout (preliminary data). Ann Rheum Dis. 2020;79:1761-2. doi:10.1136/annrheumdis-2020-eular.5164.

Елисеев МС, Желябина ОВ, Мукагова МВ, Насонов ЕЛ. Клинический опыт применения блокатора интерлейкина 1β канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015;9(2):16-22. doi:10.14412/1996-70122015-2-16-22.

Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin-1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(2):16-22. (In Russ.). doi:10.14412/1996-70122015-2-16-22.

Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-61. doi:10.1056/NEJMoa050373.

Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-8. doi:10.1002/art.24209.

Feng X, Li Y, Gao W. Significance of the initiation time of urate lowering therapy in gout patients: a retrospective research. Joint Bone Spine. 2015 Dec;82(6):428-31. doi: 10.1016/j.jbspin.2015.02.021. Epub 2015 Oct 9.

Елисеев МС, Барскова ВГ, Денисов ИС. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив. 2015;87(5):10-15.

Eliseev MS, Barskova VG, Denisov IS. Dynamics of clinical manifestations of gout in men (data from 7-year retrospective observation). Terapevticheskii arkhiv. 2015;87(5): 10-15. (In Russ.).

Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189-92. doi: 10.1002/art.1780150209.

Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of uratelowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002 Aug;47(4):356-60. doi: 10.1002/art.10511.

Eliseev M, Zhelyabina O, Chikina M, Vladimirov S. Assessment of therapy adherence and treatment results in gout patients who attended schools for patients and in those who did not. Ann Rheum Dis. 2018; 77(Suppl):A654. doi:10.1136/annrheumdis2018-eular.6520

Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurseled care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018; 392(10156):1403-12. doi:10.1016/S01406736(18)32158-5.

Goldfien R, Pressman A, Jacobson A, et al. A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial. Perm J. 2016;20(3):15-234. doi:10.7812/TPP/15-234.

Mikuls TR, Cheetham TC, Levy GD, et al. Adherence and Outcomes with UrateLowering Therapy: A Site-Randomized Trial. Am J Med. 2019;132(3):354-61. doi:10.1016/j.amjmed.2018.11.011.

Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the «dirty dish» hypothesis. Arthritis Rheum. 2011;63(12): 4002-6. doi:10.1002/art.30649.

Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005; 102(11):4134-9. doi:10.1073/pnas.0409500102.

Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704-9. doi:10.1097/FPC.0b013e328330a3b8.

White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200-10. doi:10.1056/NEJMoa1710895.

Jansen TLTA, Janssen M. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clin Rheumatol. 2019;38(1):263-5. doi:10.1007/s10067-018-4396-4.

Kang EH, Kim SC. Cardiovascular Safety of Urate Lowering Therapies. Curr Rheumatol Rep. 2019 Jul 24;21(9):48. doi: 10.1007/s11926-019-0843-8.

Liu CW, Chang WC, Lee CC, et al. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia – A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2019;29(10):1011-22. doi:10.1016/j.numecd.2019.06.016.

Елисеев МС. Сердечно-сосудистая безопасность фебуксостата. Анализ исследования CARES. Современная ревматология. 2018;12(4):42-6. doi:10.14412/1996-7012-2018-4-42-46.

Eliseev MS. Cardiovascular safety of febuxostat. Analysis of the CARES study. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(4):42-6. (In Russ.). doi:10.14412/1996-7012-2018-4-42-46.

Zhang M, Solomon DH, Desai RJ, et al. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study. Circulation. 2018;138(11):1116-26. doi:10.1161/CIRCULATIONAHA.118.033992

Елисеев МС, Чикина МН. Одноцентровое открытое проспективное исследование влияния комбинированной уратснижающей и противовоспалительной терапии на течение подагры. Русский медицинский журнал. Медицинское обозрение. 2019;11(II):90-5.

Eliseev MS, Chikina MN. A single-center open prospective study of the effect of combined urate-lowering and anti-inflammatory therapy on the course of gout. Russkii meditsinskii zhurnal. Meditsinskoe obozrenie. 2019; 11(II):90-5. (In Russ.).

Чикина МН, Елисеев МС, Желябина ОВ. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020;14(2):97-103. doi:10.14412/1996-70122020-2-97-103

Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(2): 97-103. (In Russ.). doi:10.14412/1996-70122020-2-97-103

Baumgartner S, Yeh LT, Shen Z, et al. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout. J Clin Pharmacol. 2018;58(9):1164-70. doi:10.1002/jcph.1124.

Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017;69(9):1903-13. doi:10.1002/art.40159.

Tausche AK, Alten R, Dalbeth N, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56(12): 2170-8. doi:10.1093/rheumatology/kex350.

Becker MA, Baraf HS, Yood RA, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013;72(9):1469-74. doi:10.1136/annrheumdis-2012-201795.

The authors declare that there are no conflicts of interest present.